PTGER4 and breast carcinoma: Indeed a synergistic action on tumor regression and animal survival was shown with an EP4 antagonist in combination of either of two checkpoint inhibitors, anti-CTLA4 and anti-PD-1 antibodies, in murine colon and breast cancer models [101].